Metabolic health-focused drug developer Kalohexis is eyeing a debut on the public market after confidentially filing for an initial public offering (IPO) – potentially adding it to a growing list of American biotechs that have opted to go public thus far in 2026.
Though the details around the biotech's public debut remain sparse, the company notes it has submitted a draft registration statement to the US Securities and Exchange Commission (SEC) related to the IPO. Kalohexis is yet to determine how many shares it will offer and at what price upon its potential public market debut.
Kalohexis' proposed IPO comes four months after the clinical-stage biotech spun out of peptide therapeutic specialist Endevica Bio in March 2026, as it looks to progress its range of therapies for both obesity and cancer cachexia.
At the core of Kalohexis' approach is the melanocortin system, which is involved in balancing energy intake and expenditure, while also regulating appetite and inflammation. By modulating this system through the melanocortin-3 and -4 receptors (MC3R/MC4R), the biotech proposes that it can treat "many metabolic disorders".
Currently, Kalohexis has two lead, clinical-stage pipeline programmes to its name.